Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of ...

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which ...

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard ...

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call ...